Shilpa Medicare Limited announced its financial results for the second quarter of fiscal year 2027, reporting its highest-ever quarterly revenue and EBITDA. The company achieved revenue of INR538 crores, a 35% year-on-year increase, and EBITDA of INR151 crores, up 37% year-on-year. This performance was driven by robust growth across all four business segments: API, CDMO, formulation, and biologics.
Shilpa Medicare Achieves Record Financial Performance
Shilpa Medicare Limited has reported a significant milestone in its Q2 FY27 financial results, achieving its highest-ever quarterly revenue and highest-ever EBITDA. The company posted revenues of INR538 crores, marking a robust 35% year-on-year growth. Concurrently, the EBITDA for the quarter reached INR151 crores, representing a 37% year-on-year increase, with an EBITDA margin of 28%.
Strong Growth Across Business Segments
This exceptional performance was underpinned by strong growth across all four key business segments: API, CDMO, formulation, and biologics. The company highlighted that the hardest years of investing ahead of revenue are now behind them, and the years of harvesting are beginning. Shilpa Medicare emphasized its strategy to compete on difficulty and complexity of molecules rather than price alone.
Segment-wise Highlights
In the API segment, Shilpa Medicare delivered its highest ever quarterly revenue, confident in continuing this momentum. The formulation division saw a year-on-year growth of over 50%, with the India business growing 2.5x year-on-year, led by the novel first-in-class treatment for NAFLD.
The Biologics division now contributes 12% of revenue, with a portfolio of 7 biosimilars. The company also noted strong opportunities in new biological entities and highlighted that CDMO will remain a strong and fast-growing segment within biologics.
Financial Overview and Outlook
For the first half of FY27, revenues stood at INR1,007 crores, a 44% year-on-year growth. EBITDA for the half-year was INR290 crores, up 40% year-on-year, with an EBITDA margin of 29%. The company reported a PAT of INR180 crores for the first half, a near 100% growth compared to the previous year’s first half. Net debt remains stable at INR612 crores, and ROCE improved to 13.3%.
Keshav Bhutada, Executive Director and CEO of Shilpa Pharma Life Sciences, expressed confidence in monetizing investments and stated that Shilpa Medicare is a profitable, deleveraged, multi-engine specialty pharma company with a dense pipeline of differentiated launches.
Source: BSE
